DUBLIN--(BUSINESS WIRE)--The "Cancer/Tumor Profiling Market Research Report by Technology, Cancer Type, Biomarker Type, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Cancer/Tumor Profiling Market size was estimated at USD 9,872.31 million in 2021, USD 11,656.24 million in 2022, and is projected to grow at a CAGR 18.32% to reach USD 27,094.28 million by 2027.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer/Tumor Profiling Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer/Tumor Profiling Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer/Tumor Profiling Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer/Tumor Profiling Market?
4. What is the competitive strategic window for opportunities in the Global Cancer/Tumor Profiling Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer/Tumor Profiling Market?
6. What is the market share of the leading vendors in the Global Cancer/Tumor Profiling Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer/Tumor Profiling Market?
Market Dynamics
Drivers
- Rising funding from government for devising cancer diagnosing methods
- Increasing incidence of cancer
- Increasing use of biomarkers in cancer profiling
Restraints
- High capital investment in Cancer/Tumor Profiling devices
Opportunities
- Increasing demand for personalized medicine
- Growing need for point-of-care diagnostics
Challenges
- Low biomarker discovery-to-approval ratio
Companies Mentioned
- Agendia, Inc.
- Boreal Genomics Inc
- Caris Life Sciences
- Foundation Medicine
- Genomic Health Inc.
- GenScript Biotech Corporation
- Guardant Health, Inc.
- Helomics Corporation
- HistoGeneX NV
- HTG Molecular Diagnostics, Inc.
- Illumina, Inc.
- NanoString Technologies, Inc.
- NeoGenomics Laboratories, Inc.
- Omniseq, Inc.
- Perthera, Inc.
- QIAGEN N.V.
- Ribomed Biotechnologies, Inc.
- Roche Diagnostics
- Sysmex Corporation
- Tempus Labs
For more information about this report visit https://www.researchandmarkets.com/r/1qunge
